SCHEMBL1698539

SCHEMBL1698539

CC(C)N1CCNC(=O)C1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 3/20 0.67
TOP2B Q02880 3/20 0.67
ALDH1A1 P00352 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
THRB P10828 1/20 0.38
PTGS1 P23219 2/20 0.37
LMNA P02545 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.35
GFER P55789 1/20 0.35
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CDA P32320 1/20 0.32
HSP90AA1 P07900 1/20 0.31
OR51E2 Q9H255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11840238 0.88 TOP2A (0.53) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL22212257 0.83 TOP2A (0.62) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL4019369 0.81 TOP2A (0.50) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL19505555 0.80 TOP2A (1.00) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL19544953 0.80 TOP2A (0.59) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL25999811 0.80 TOP2A (0.59) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL12980280 0.79 TOP2A (0.57) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL30405945 0.79 TOP2A (0.57) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL12841739 0.79 TOP2A (0.57) TOP2ATOP2BALDH1A1TDP1MAPT
SCHEMBL14853058 0.77 TOP2A (0.56) TOP2ATOP2BALDH1A1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF CORNELL UNIVERSITY (US) 2024-07-18 US disclosed
US-20240239772-A1 PROTEASE INHIBITORS AND METHODS OF USE THE CLEVELAND CLINIC FOUNDATION 2024-07-18 US disclosed
US-20240228464-A9 TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2024-07-11 US disclosed
US-20240207300-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS SINAI HEALTH SYSTEM (CA) 2024-06-27 US disclosed
US-12018015-B2 Methods and compositions for targeting PD-L1 ALIGOS THERAPEUTICS, INC. (US) 2024-06-25 US disclosed
US-12018017-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
US-12018017-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
US-20080167340-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2008-07-10 US disclosed
US-20080167340-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2008-07-10 US disclosed
US-7384937-B2 Fused heterocyclic compounds and use thereof BRISTOL-MYERS SQUIBB CO. (US) 2008-06-10 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed
US-20080045509-A1 SUBSTITUTED BENZYL AMINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
WO-2008002820-A2 SUBSTITUTED BENZYL AMINE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 WO disclosed
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed
US-20070173530-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173530-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
WO-2007018941-A2 PYRIMIDYL-THIOPHENE DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167340-A1 6-Aminoisoquinoline Compounds COQ8A, PGC, AGK TOP2A 1904/4885TOP2B 2090/4885ALDH1A1 2478/4885
US-12018017-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof BAD, CASP1, BAX TOP2A 3733/4885TOP2B 4057/4885ALDH1A1 1882/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS TOP2A 113/4885TOP2B 94/4885ALDH1A1 4236/4885
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 TOP2A 4104/4885TOP2B 4257/4885ALDH1A1 2989/4885
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF UACA, ADCYAP1R1, ADCY1 TOP2A 3913/4885TOP2B 3314/4885ALDH1A1 638/4885
US-20080045509-A1 SUBSTITUTED BENZYL AMINE COMPOUNDS HRH3, HNMT, HRH4 TOP2A 1980/4885TOP2B 1953/4885ALDH1A1 1869/4885
US-12018015-B2 Methods and compositions for targeting PD-L1 CD274, PDCD1LG2, PDCD1 TOP2A 1156/4885TOP2B 1467/4885ALDH1A1 301/4885
US-20070173530-A1 6-Aminoisoquinoline Compounds COQ8A, PGC, AGK TOP2A 1904/4885TOP2B 2090/4885ALDH1A1 2478/4885
US-20240207300-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS WEE2, WEE1, KAT2A TOP2A 66/4885TOP2B 134/4885ALDH1A1 1899/4885
US-20240239772-A1 PROTEASE INHIBITORS AND METHODS OF USE ACE2, ACE, TMPRSS2 TOP2A 1748/4885TOP2B 2014/4885ALDH1A1 3658/4885
US-20240228464-A9 TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF AIFM1, BAD, IRAK1 TOP2A 3670/4885TOP2B 4132/4885ALDH1A1 1233/4885
US-20070185098-A1 Inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K19 TOP2A 3013/4885TOP2B 3611/4885ALDH1A1 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.